Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1585-1590

  Yamanegi, Koji ^a   Yamane, Junko ^a   Kobayashi, Kenta ^a   Ohyama, Hideki ^a   Nakasho, Keiji ^a   Yamada, Naoko ^a   Hata, Masaki ^a   Fukunaga, Satoru ^a   Futani, Hiroyuki ^a   Okamura, Haruki ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Histone deacetylase inhibitor; Metalloproteinase; MHC class I related chain molecule; Osteosarcoma; Valproic acid

Indexed keywords

GELATINASE A; GELATINASE B; HLA A ANTIGEN; HLA B ANTIGEN; MATRIX METALLOPROTEINASE; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VALPROIC ACID;

ADAM17 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MATRIX METALLOPROTEINASE 9 GENE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN SECRETION; UPREGULATION;

BONE NEOPLASMS; CELL LINE, TUMOR; DIPEPTIDES; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE PROTEINS; OSTEOSARCOMA; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; VALPROIC ACID;

EID: 84866443923     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1981     Document Type: Article

References (23)

1. Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943, 2008.
2. Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958, 2008.
3. Salih HR, Rammensee HG and Steinle A: Cutting edge: downregulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102, 2002. (Pubitemid 35178177)
4. Salih HR, Goehlsdorf D and Steinle A: Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67: 188-195, 2006. (Pubitemid 43673929)
5. Waldhauer I and Steinle A: Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 66: 2520-2526, 2006.
6. Boutet P, Agüera-González S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT and Valés-Gómez M: Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182: 49-53, 2009.
7. Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738, 2002. (Pubitemid 35177960)
8. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S and Pistoia V: Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6: 558-568, 2004. (Pubitemid 39411093)
9. Märten A, von Lilienfeld-Toal M, Büchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδT cell cytotoxicity. Int J Cancer 119: 2359-2365, 2006. (Pubitemid 44546956)
10. Yoo CB and Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50, 2006.
11. Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol 625: 131-142, 2009.
12. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et al: Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65: 6321-6329, 2005. (Pubitemid 40994418)
13. Schmudde M, Braun A, Pende D, Sonnenmann J, Klier U, Beck JF, Moretta L and Bröker BM: Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells. Cancer Lett 272: 110-121, 2008.
14. Zhang C, Wang Y, Zhou Z, Zhang J and Tian Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58: 1275-1285, 2009.
15. Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23: 641-648, 2009.
16. Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Nishioka T, Fukunaga S, et al: Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 24: 1621-1627, 2010.
17. Cho HJ, Lee TS, Park JB, Park KK, Choe JY, Sin DI, Park YY, Moon YS, Lee KG, Yeo JH, et al: Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40: 1069-1076, 2007.
18. Xin ZF, Kim YK and Jung ST: Risedronate inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res 28: 105, 2009.
19. Lee KH, Choi EY, Kim MK, Kim KO, Jang BI, Kim SW, Kim SW, Song SK and Kim JR: Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. Mol Cell Biochem 343: 163-171, 2010.
20. Mitmarker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, Clark OH and Shen WT: Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery 149: 504-511, 2011.
21. Vinodhkumar R, Song YS, Ravikumar V, Ramakrishnan G and Devaki T: Depsipeptide a histone deacetylase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem Biol Interact 165: 220-229, 2007. (Pubitemid 46227368)
22. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG and Steinle A: Tumor-associated MICA is shed by ADAM proteases. Cancer Res 68: 6368-6376, 2008.
23. Liu G, Atteridge CL, Wang X, Lundgren AD and Wu JD: The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of a disintegrin and metalloproteinases. J Immunol 184: 3346-3350, 2010.